ES2176432T3 - Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector. - Google Patents

Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector.

Info

Publication number
ES2176432T3
ES2176432T3 ES96901587T ES96901587T ES2176432T3 ES 2176432 T3 ES2176432 T3 ES 2176432T3 ES 96901587 T ES96901587 T ES 96901587T ES 96901587 T ES96901587 T ES 96901587T ES 2176432 T3 ES2176432 T3 ES 2176432T3
Authority
ES
Spain
Prior art keywords
treatment
cerebral ischemia
brain injury
neuroprotector
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96901587T
Other languages
English (en)
Inventor
Eskil Elmer
Hiroyuki Uchino
Marcus Keep
Merab Kokaia
Zaal Kokaia
Hakan Widner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maas Biolab LLC
Original Assignee
Maas Biolab LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maas Biolab LLC filed Critical Maas Biolab LLC
Application granted granted Critical
Publication of ES2176432T3 publication Critical patent/ES2176432T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION PROPORCIONA COMPOSICIONES Y MEDICACIONES FARMACEUTICAS UTILES PARA EL TRATAMIENTO DE LA ISQUEMIA CEREBRAL, LESION CEREBRAL Y TRASTORNOS CEREBRALES MEDIANTE MEDICACION DE TRATAMIENTO ACTIVO CON CICLOSPORINA A, VARIANTES O DERIVADOS DE LA MISMA FARMACEUTICAMENTE ACEPTABLES, EN CONDICIONES, SITUACIONES Y METODOS EN DONDE LA BARRERA HEMATOENCEFALICA SE HA ABIERTO, ROTO, CORTOCIRCUITADO, QUEBRANTADO, OBVIADO O CRUZADO, TALES QUE LA CICLOSPORINA A, VARIANTES O DERIVADOS DE LA MISMA FARMACEUTICAMENTE ACEPTABLES ENTRAN EN CONTACTO CON NEURONAS Y CELULAS DE SOPORTE NEURONAL. LOS METODOS PARA EL USO DE DICHAS COMPOSICIONES Y MEDICACIONES FARMACEUTICAS ESTAN INCLUIDOS EN LA INVENCION. TAMBIEN ESTAN INCLUIDAS EN LA INVENCION LOS ESTADOS, SITUACIONES Y METODOS CON QUE LA MEDICACION DE TRATAMIENTO ACTIVO PUEDE ENTRAR EN CONTACTO CON NEURONAS Y CELULAS DE SOPORTE NEURONAL.
ES96901587T 1995-01-20 1996-01-18 Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector. Expired - Lifetime ES2176432T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500209A SE520730C2 (sv) 1995-01-20 1995-01-20 Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel

Publications (1)

Publication Number Publication Date
ES2176432T3 true ES2176432T3 (es) 2002-12-01

Family

ID=20396911

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96901587T Expired - Lifetime ES2176432T3 (es) 1995-01-20 1996-01-18 Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector.

Country Status (18)

Country Link
US (1) US5972924A (es)
EP (1) EP0813420B1 (es)
JP (1) JP3643380B2 (es)
CN (1) CN1123359C (es)
AP (1) AP734A (es)
AT (1) ATE218360T1 (es)
AU (1) AU712974B2 (es)
CA (1) CA2210241C (es)
CZ (1) CZ291233B6 (es)
DE (1) DE69621603T2 (es)
DK (1) DK0813420T3 (es)
ES (1) ES2176432T3 (es)
MX (1) MX9706362A (es)
NZ (1) NZ300699A (es)
PT (1) PT813420E (es)
RU (1) RU2194527C2 (es)
SE (1) SE520730C2 (es)
WO (1) WO1996022104A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711795C2 (de) * 1997-03-21 2001-03-08 Apogepha Arzneimittel Gmbh Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
AP1040A (en) * 1998-09-17 2002-01-30 Panacea Biotec Ltd A novel composition containing cyclosporin.
HK1040617A1 (zh) * 1998-09-23 2002-06-21 马库斯‧基普 用於選擇性神經元輻射防護的神經親免素類物質
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
JP2002541162A (ja) * 1999-04-13 2002-12-03 ノース・ショア−ロング・アイランド・ジューイッシュ・リサーチ・インスティテュート 発作による脳障害防止法
AU7353300A (en) 1999-09-08 2001-04-10 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
DE19961733A1 (de) * 1999-12-21 2001-06-28 Ciclomulsion Ag Cyclosporin(e) enthaltende hypertone pharmazeutische Zubereitung zur Anwendung bei neurologischen Erkrankungen und als Neuroprotektivum sowie Verfahren zu ihrer Herstellung
KR20010069066A (ko) * 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1274377A2 (en) * 2000-04-07 2003-01-15 The General Hospital Corporation doing business as Massachusetts General Hospital Methods and apparatus for thermally affecting tissue
WO2002028331A1 (en) 2000-10-05 2002-04-11 Seacoast Technologies, Inc. Expandable device for thermal therapy including spiral element
MXPA03006666A (es) 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US6936589B2 (en) * 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
WO2003033526A2 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
WO2004087063A2 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
RU2265415C2 (ru) * 2003-05-19 2005-12-10 Челябинский государственный институт лазерной хирургии Способ реваскуляризации инфарктных очагов головного мозга
RU2275195C2 (ru) * 2003-06-19 2006-04-27 Наталья Борисовна Кармен Средство для защиты головного мозга от гипоксически-ишемического повреждения
RU2255739C2 (ru) * 2003-07-14 2005-07-10 Оренбургская государственная медицинская академия Способ лечения ишемического инсульта в острейший период
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
KR101414810B1 (ko) * 2004-08-30 2014-07-18 주식회사 유스팜인터내셔널 국소 허혈 모델에서의 가용화 ｕｄｃａ의 신경보호 효과
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
WO2008024660A2 (en) * 2006-08-23 2008-02-28 The University Of Montana Method of reducing neuronal cell damage
PT2120991E (pt) * 2007-02-12 2014-05-02 Biotempt Bv Tratamento d a hemorragia traumática com oligopéptidos curtos
EP2547352A4 (en) * 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
RU2475233C2 (ru) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
JP6144627B2 (ja) 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク． アミノ酸１および３で修飾されたシクロスポリン類似体分子
CN102784102A (zh) * 2012-08-28 2012-11-21 赵继红 一种河豚毒素口服液态制剂及其制备方法
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
JP2021525737A (ja) 2018-05-30 2021-09-27 ザップ サージカル システムズ， インコーポレイテッド 重要構造近くにおける放射線外科的神経調節
WO2021048871A1 (en) 2019-09-15 2021-03-18 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for treating neurological disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1138164A1 (ru) * 1963-04-25 1985-02-07 Shadurskij Konstantin S Антигистаминное средство "димебон
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US5273754A (en) * 1992-03-27 1993-12-28 Mann Morris A Appetite suppressant composition and method relating thereto

Also Published As

Publication number Publication date
PT813420E (pt) 2002-10-31
NZ300699A (en) 1998-05-27
SE9500209L (sv) 1996-07-21
RU2194527C2 (ru) 2002-12-20
AU4592496A (en) 1996-08-07
CN1123359C (zh) 2003-10-08
EP0813420A1 (en) 1997-12-29
SE520730C2 (sv) 2003-08-19
CA2210241C (en) 2000-06-20
MX9706362A (es) 1998-07-31
SE9500209D0 (sv) 1995-01-20
DE69621603T2 (de) 2002-09-19
AP734A (en) 1999-02-15
EP0813420B1 (en) 2002-06-05
DK0813420T3 (da) 2002-09-30
AU712974B2 (en) 1999-11-18
CZ291233B6 (cs) 2003-01-15
JP3643380B2 (ja) 2005-04-27
DE69621603D1 (de) 2002-07-11
JPH11504617A (ja) 1999-04-27
ATE218360T1 (de) 2002-06-15
WO1996022104A1 (en) 1996-07-25
CN1178469A (zh) 1998-04-08
US5972924A (en) 1999-10-26
CZ233697A3 (cs) 1998-07-15
AP9701049A0 (en) 1997-10-31
CA2210241A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
MX9706362A (es) Tratamiento para isquemia cerebral y daño cerebral con agentes neuroprotectores.
IL180528A0 (en) Pharmaceutical formulations for treating mitochondrial disorders
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EP0998925A4 (en) TOPICAL ADMINISTRATION COMPOSITIONS CONTAINING VITAMINS D AND VITAMINS K
ES2187822T3 (es) Comprimidos de disgregacion rapida.
WO2002043652A3 (en) Anti-proliferative drugs
ECSP056076A (es) Sistema de suministro para droga y terapia celular
BR0012387A (pt) Composição para tratamento de distúrbios de secreção externa
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
PT946157E (pt) Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
DK0737069T3 (da) Deuterede aktive stoffer til transdermal administrering
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
WO2004087105A8 (en) Combination formulations of platinum agents and fluoropyrimidines
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.